Dr. Zihao Wang is the Chief Executive Officer at Immorna and Co-founder of the Immorna family of companies. Dr. Wang is a seasoned entrepreneur and established biopharmaceutical veteran. He has over 14 years of biotech R&D and leadership experience. He is one of the pioneers in self-replicating mRNA (srRNA) CMC development and is the mastermind behind the development of the mRNA platform technologies at Immorna, which include an improved next generation srRNA, conventional mRNA, and circular RNA. Dr. Wang pioneers the application of srRNA-LNP against oncology indications.

Prior to founding the Immorna family of companies, Dr. Wang held various R&D roles at GSK Vaccines, Novartis Vaccines and Diagnostics, Grifols SA, etc. During his tenure at Novartis and GSK, he spent more than 7 years working directly on srRNA CMC development and the application of srRNA technology against various viral infectious diseases.

Mr. Zhijun Guo is the Chief Technology Officer at Immorna and Co-founder of the Immorna family of companies. He has more than 30 years of scientific and leadership experience in the infectious disease vaccine industry.

Prior to co-founding Immorna with Dr. Zihao Wang, Mr. Guo was Associate General Manager at King-Cell Biotechnology (Shanghai) where he established the full quality system to support the drug whole lifecycle management and led the GMP compliance taskforce. Prior to King-cell, Mr. Guo worked for more than 15 years at Tianyuan Biopharmaceutical Co. Ltd. (part of Novartis Vaccine Diagnostics, then GSK Vaccines) with increasing technical and leadership roles. He was Head of the Manufacturing Science & Technology function before he left GSK Vaccines. Mr. Guo is a well-recognized expert in CMC development, tech transfer, process validation, and GMP manufacturing. He also has extensive experience in regulatory submission for all phases of vaccine clinical trials and commercial product registration. He led the successful registration of GSK and/or Novartis’ Rabies Vaccine, Quadrivalent Influenza Vaccine, and HPV Vaccine.

Mr. Guo holds an MBA degree from the University of Montpellier in France.

Dr. Yuanqing Liu is the Chief Scientific Officer at Immorna China. Dr. Liu is a surgeon, an immunologist, and a seasoned translational research leader in the vaccine industry. His early research in oncology established, with others, a role of myeloid-derived suppressor cells in cancer microenvironment.

Dr. Liu has over 13 years of big-pharma experience. Prior to joining Immorna, he held various R&D roles with increased responsibility at Sanofi Pasteur France. He has extensive knowledge in development of vaccines against infectious diseases and cancer for adults as well, as pediatric populations. He is an expert in early product PoC demonstration in compliance with FDA, EMEA and other regulatory jurisdictions.

Dr. Liu received his M.D. degree from Shanghai Medical School, Fudan University in Shanghai, and his Ph.D. in Applied Biological Sciences from Free University Brussels (Flandres) in Belgium.

Dr. NgocDiep (“Diep”) Le is the President and Global CMO of Immorna. In this role, she is responsible for creating the company’s medical vision and leads the development and execution of the clinical development plan globally. 


Dr. Le brings to Immorna over 20 years of drug development experience across early-to-late phases, with a track record of success in bringing innovative medicines to patients. Prior to joining Immorna, Dr. Le served as CMO at NeolmmuneTech where she successfully filed 10 Investigational New Drug applications, and at Verastem where she led the submission and achieved FDA approval for the company’s first product. Previously, she held leadership positions with increasing responsibilities at Medlmmune/AstraZeneca, Novartis, GSK and Amgen, most notable for her role in leading the GSK MEK inhibitor program from Phase 1 First-in-Human study to Phase 3 registrational studies and approval.


Dr. Le received her B.S. in Biology from the California Institute of Technology, earned her M.D. and Ph.D. degrees from Stanford University School of Medicine. She completed a Medical Oncology Fellowship at the Duke Comprehensive Cancer Center.

Dr. Jeffrey Ulmer is the Chief Scientific Advisor at Immorna. He has spent more than 30 years in vaccines R&D at Merck Research Laboratories, Chiron Corporation, Novartis and GlaxoSmithKline. He is also currently President of TechImmune LLC.

Dr. Ulmer’s most recent leadership positions included Global Head, External R&D; Head, Preclinical R&D; and Program Head, Technical R&D. His scientific focus has been vaccine technology platforms, including DNA and mRNA vaccines, viral vectors and adjuvants. He has published over 210 scientific articles, is an inventor on 11 patents, and is a Fellow of the International Society of Vaccines where he serves as Treasurer. 

Dr. Ulmer has received his Ph.D. in biochemistry from McGill University and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine.

Ms. Zhang is the Senior Vice President, Head of Strategic Operations at Immorna. She has about 10 years of experience in venture capital investment focusing on healthcare.

Prior to joining Immorna, Ms. Zhang was a Director of Investment at Co-Ventures, an Associate at Everest Venture Capital, and an industry researcher in Grains Valley Venture Capital. Her investment portfolio included Ascentage Pharma (06855.HK), HaploX, Kidney Health, Neologics Bioscience, and InsureSmart.

Ms. Zhang holds an M.S. degree in Physiology and a B.S. degree in Basic Medical Science, both from Peking University Health Science Center.

Dr. Marcin Bugno is the Vice President, Head of RNA Development. He has 20+ years of R&D experience in academia, biotech and large pharma companies.

Prior to joining Immorna, Dr. Bugno served as Senior Director, Analytical and Process Development at Istari Oncology and Director, Technical R&D Drug Substance at GSK Vaccines, where he supported pre-clinical and clinical stage immuno-oncology and vaccine programs. He has experience in analytical and process development for recombinant viral products, protein biologics, and mRNA vaccines. Dr. Bugno published 18 research papers and 3 patents in the field of process science, cell biology, virology, biochemistry and molecular biology.

Dr. Bugno holds a Ph.D. in Biochemistry and Molecular Biology from Jagiellonian University, Poland and a B.Sc. in Biotechnology from University of Wolverhampton, England.